Security
INTERPACE BIOSCIENCES INC Common Stock · IDXG
IDXGOTCCommon stockCurrentCIK 1054102Updated Nov 2, 2026
Name history
Interpace Diagnostics Group, Inc. · through Nov 1, 2019PDI INC · through Dec 22, 2015PROFESSIONAL DETAILING INC · through Nov 13, 2002
IDXG price & chart
Loading TradingView…
OTC:IDXG on TradingView ↗About the company
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.
In the news
No coverage from other publishers is available.
Recent filings
S-1/A filing
FWP - filed by INTERPACE BIOSCIENCES, INC. regarding INTERPACE BIOSCIENCES, INC.
Results of Operations and Financial Condition
Items 2.02, 9.01
S-1/A filing
S-1 filing
Show 5 more recent filings
S-8 filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 5.03, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 12,036,000Source | 14,039,000Source | 34,549,000Source | 12,335,000Source | 12,972,000Source | 33,409,000Source | 14,494,000Source | 12,142,000Source | 33,838,000Source | 12,142,000Source | 13,021,000Source | 15,979,000Source |
| Property, Plant and Equipment, NetUSD | 1,541,000Source | 1,352,000Source | 1,621,000Source | 1,366,000Source | 1,126,000Source | 1,315,000Source | 1,277,000Source | 925,000Source | 1,423,000Source | 925,000Source | 790,000Source | 480,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,423,000Source | 1,400,000Source | 2,688,000Source | 502,000Source | 500,000Source | 2,647,000Source | 1,196,000Source | 2,812,000Source | 2,505,000Source | 2,812,000Source | 3,498,000Source | 4,828,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,966,000Source | 7,293,000Source | 6,311,000Source | 7,231,000Source | 6,206,000Source | 5,925,000Source | 8,768,000Source | 5,006,000Source | 5,649,000Source | 5,006,000Source | 4,983,000Source | 5,032,000Source |
| Inventory, NetUSD | 1,104,000Source | 1,220,000Source | 1,085,000Source | 973,000Source | 1,231,000Source | 961,000Source | 1,209,000Source | 1,154,000Source | 1,114,000Source | — | 1,227,000Source | 1,224,000Source |
| Assets, CurrentUSD | 9,130,000Source | 9,100,000Source | 10,968,000Source | 9,504,000Source | 9,500,000Source | 9,963,000Source | 11,654,000Source | 9,416,000Source | 9,900,000Source | 9,416,000Source | 10,322,000Source | 12,154,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,320,000Source | 1,532,000Source | 1,001,000Source | 1,420,000Source | 1,635,000Source | 1,110,000Source | 1,518,000Source | 1,756,000Source | 1,217,000Source | 1,756,000Source | 1,864,000Source | 2,439,000Source |
| Other Assets, NoncurrentUSD | 45,000Source | 45,000Source | 44,000Source | 45,000Source | 45,000Source | 44,000Source | 45,000Source | 45,000Source | 44,000Source | 45,000Source | 45,000Source | 45,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,334,000Source | 25,185,000Source | 11,305,000Source | 13,548,000Source | 25,462,000Source | 10,327,000Source | 15,076,000Source | 26,747,000Source | 11,475,000Source | 20,374,000Source | 28,157,000Source | 32,515,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 407,000Source | 406,000Source | 640,000Source | 407,000Source | 406,000Source | 640,000Source | 407,000Source | 406,000Source | 407,000Source | 406,000Source | 405,000Source | 405,000Source |
| Retained Earnings (Accumulated Deficit)USD | -233,462,000Source | -244,405,000Source | -209,926,000Source | -234,373,000Source | -245,685,000Source | -210,084,000Source | -233,733,000Source | -247,747,000Source | -210,805,000Source | -241,374,000Source | -248,215,000Source | -249,017,000Source |
| Stockholders' Equity Attributable to ParentUSD | -298,000Source | -50,538,000Source | 23,244,000Source | -1,213,000Source | -52,278,000Source | 23,082,000Source | -582,000Source | -54,768,000Source | 22,363,000Source | -54,768,000Source | -61,672,000Source | -63,072,000Source |
| Additional Paid in Capital, Common StockUSD | 234,829,000Source | 188,363,000Source | 234,608,000Source | 234,822,000Source | 188,277,000Source | 234,604,000Source | 234,813,000Source | 188,224,000Source | 234,833,000Source | 188,224,000Source | 188,146,000Source | 187,516,000Source |
| Liabilities and EquityUSD | 12,036,000Source | 14,039,000Source | 34,549,000Source | 12,335,000Source | 12,972,000Source | 33,409,000Source | 14,494,000Source | 12,142,000Source | 33,838,000Source | 12,142,000Source | 13,021,000Source | 15,979,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,945,000Source | 5,900,000Source | 4,951,000Source | 7,149,000Source | 7,100,000Source | 3,962,000Source | 8,678,000Source | 18,973,000Source | 5,103,000Source | 12,600,000Source | 17,474,000Source | 14,283,000Source |
| Operating Lease, Liability, CurrentUSD | 419,000Source | 305,000Source | 458,000Source | 406,000Source | 319,000Source | 445,000Source | 394,000Source | 375,000Source | 431,000Source | — | 377,000Source | 578,000Source |
| Accounts Payable, CurrentUSD | 1,411,000Source | 1,701,000Source | 1,555,000Source | 1,250,000Source | 1,761,000Source | 805,000Source | 1,733,000Source | 1,363,000Source | 983,000Source | 1,363,000Source | 1,544,000Source | 1,050,000Source |
| Operating Lease, Liability, NoncurrentUSD | 864,000Source | 1,189,000Source | 516,000Source | 974,000Source | 1,286,000Source | 635,000Source | 1,080,000Source | 1,359,000Source | 752,000Source | 1,359,000Source | 1,472,000Source | 1,848,000Source |
| Other Liabilities, NoncurrentUSD | 5,525,000Source | 5,227,000Source | 5,838,000Source | 5,425,000Source | 5,146,000Source | 5,730,000Source | 5,318,000Source | 5,072,000Source | 5,620,000Source | 5,072,000Source | 4,968,000Source | 4,701,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 118,000Source | 95,000Source | 425,000Source | 300,000Source | 1,026,000Source | 2,560,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 4,000Source | 9,000Source | 4,000Source | 15,000Source | 35,000Source | 291,000Source | 630,000Source | 1,258,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 276,000Source | 224,000Source | -2,895,000Source | 3,466,000Source | -49,000Source | 133,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -47,000Source | 61,000Source | -807,000Source | 120,000Source | 489,000Source | -735,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -21,254,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 283,000Source | 1,235,000Source | 5,831,000Source | 4,646,000Source | 3,789,000Source | -7,692,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -141,000Source | — | -356,000Source | -876,000Source | -87,000Source | 6,206,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 141,000Source | — | 356,000Source | 876,000Source | 470,000Source | 322,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | -1,500,000Source | -4,431,000Source | -5,807,000Source | -5,032,000Source | 3,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 142,000Source | -265,000Source | 1,044,000Source | -2,037,000Source | -1,330,000Source | 1,514,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,423,000Source | 2,113,000Source | 2,688,000Source | 502,000Source | 2,647,000Source | 1,196,000Source | 2,505,000Source | 1,461,000Source | 3,498,000Source | 4,828,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 168,000Source | 625,000Source | 1,092,000Source | 971,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 101,000Source | 274,000Source | 270,000Source | 251,000Source |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | 4,000Source | — | — | — | — | — | 34,000Source | — | — |
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | — | — | — | — | — | — | — | — | — | 112,000Source | 158,000Source |
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 861,000Source | 1,270,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,000Source | 86,000Source | — | 9,000Source | — | 15,000Source | 35,000Source | 291,000Source | 630,000Source | 1,191,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 11,000Source | 58,000Source | — | 42,000Source | 60,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 900,000Source | 1,300,000Source |
| General and Administrative ExpenseUSD | — | — | 2,057,000Source | 2,538,000Source | 2,976,000Source | 2,661,000Source | 2,451,000Source | 2,550,000Source | 9,480,000Source | 9,486,000Source | 9,363,000Source | 10,973,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 8,433,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 3,964,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | 1,100,000Source | 1,800,000Source | 4,100,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 1,011,000Source | 1,758,000Source | 266,000Source | -533,000Source | 831,000Source | 1,754,000Source | 24,984,000Source | 6,946,000Source | 1,112,000Source | -5,865,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -100,000Source | -82,000Source | -108,000Source | -107,000Source | -110,000Source | -107,000Source | -409,000Source | -244,000Source | -310,000Source | -16,093,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -1,011,000Source | -1,758,000Source | -266,000Source | 533,000Source | -831,000Source | -1,754,000Source | — | 8,100,000Source | 2,800,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -11,000Source | 4,000Source | 64,000Source | — | 302,000Source | 18,000Source | -21,210,000Source | 4,000Source | 17,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 911,000Source | 1,676,000Source | 158,000Source | -640,000Source | 721,000Source | 1,647,000Source | 24,575,000Source | 6,702,000Source | 802,000Source | -21,958,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | 24,575,000Source | 6,238,000Source | — | — |
| Operating ExpensesUSD | — | — | 4,294,000Source | 5,601,000Source | 5,332,000Source | 5,744,000Source | 4,781,000Source | 5,541,000Source | 20,046,000Source | 21,817,000Source | 21,100,000Source | 21,848,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 200,000Source | 100,000Source | 100,000Source | — | — | 600,000Source | 700,000Source | 800,000Source | 900,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,000Source | 10,000Source | 9,000Source | -10,000Source | 10,000Source | 7,000Source | — | — | -667,000Source | -1,211,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -115,000Source | -394,000Source | 9,000Source | -16,000Source | 10,000Source | 21,000Source | -142,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 108,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,756,000Source | 12,295,000Source | 9,131,000Source | 9,232,000Source | 9,032,000Source | 11,515,000Source | 38,728,000Source | 46,926,000Source | 40,214,000Source | 31,838,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | 1,145,000Source | 2,301,000Source | 321,000Source | -468,000Source | 1,123,000Source | 1,829,000Source | 4,084,000Source | 8,108,000Source | 2,804,000Source | -3,617,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,000Source | 10,000Source | 9,000Source | -10,000Source | 10,000Source | 7,000Source | — | — | -667,000Source | -1,211,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 1,000,000Source | 1,762,000Source | 330,000Source | -533,000Source | 1,133,000Source | 1,772,000Source | 3,774,000Source | 6,950,000Source | 1,129,000Source | -5,836,000Source |
| Income Tax Expense (Benefit)USD | — | — | -11,000Source | 4,000Source | 64,000Source | — | 302,000Source | 18,000Source | -21,210,000Source | 4,000Source | 17,000Source | 29,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 911,000Source | 1,676,000Source | 158,000Source | -640,000Source | 721,000Source | 1,647,000Source | 24,575,000Source | 6,702,000Source | 802,000Source | -21,958,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.21Source | 0.38Source | 0.01Source | -0.14Source | 0.03Source | 0.37Source | 5.55Source | 1.42Source | 0.19Source | -5.18Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | 0.38Source | 0.01Source | -0.14Source | 0.03Source | 0.06Source | 0.89Source | 0.4Source | 0.18Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,425,000Source | 4,393,000Source | 27,701,000Source | 4,423,000Source | 22,786,000Source | 4,420,000Source | 4,424,000Source | 4,387,000Source | 4,317,000Source | 4,238,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 27,695,000Source | 4,423,000Source | 27,713,000Source | 4,423,000Source | 27,707,000Source | 27,704,000Source | 27,695,000Source | 15,734,000Source | 4,364,000Source | 4,238,000Source |
| Additional Financial Items | ||||||||||||
| Accretion Expense, Including Asset Retirement ObligationsUSD | — | — | — | — | — | — | — | — | — | — | 112,000Source | 158,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 900,000Source | 1,300,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 44,000Source | 4,000Source | 17,000Source | 29,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 111,000Source | 85,000Source | 127,000Source | 101,000Source | 118,000Source | 95,000Source | — | — | 200,000Source | 200,000Source |
| General and Administrative ExpenseUSD | — | — | 2,057,000Source | 2,538,000Source | 2,976,000Source | 2,661,000Source | 2,451,000Source | 2,550,000Source | 9,480,000Source | 9,486,000Source | 9,363,000Source | 10,973,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 8,433,000Source |
| Gross ProfitUSD | — | — | 5,439,000Source | 7,902,000Source | 5,653,000Source | 5,276,000Source | 5,904,000Source | 7,370,000Source | 24,130,000Source | 29,925,000Source | 23,904,000Source | 18,231,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | 1,100,000Source | 1,800,000Source | 4,100,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 1,011,000Source | 1,758,000Source | 266,000Source | -533,000Source | 831,000Source | 1,754,000Source | 24,984,000Source | 6,946,000Source | 1,112,000Source | -5,865,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0.23Source | 0.4Source | 0.01Source | -0.12Source | 0.04Source | 0.4Source | 5.65Source | 1.48Source | 0.26Source | -1.38Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | 0.04Source | 0.4Source | 0.01Source | -0.12Source | 0.03Source | 0.06Source | 0.9Source | 0.41Source | 0.25Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -100,000Source | -82,000Source | -108,000Source | -107,000Source | -110,000Source | -107,000Source | -409,000Source | -244,000Source | -310,000Source | -16,093,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -1,011,000Source | -1,758,000Source | -266,000Source | 533,000Source | -831,000Source | -1,754,000Source | — | 8,100,000Source | 2,800,000Source | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -112,000Source | -158,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | 24,575,000Source | 6,238,000Source | — | — |
| Operating ExpensesUSD | — | — | 4,294,000Source | 5,601,000Source | 5,332,000Source | 5,744,000Source | 4,781,000Source | 5,541,000Source | 20,046,000Source | 21,817,000Source | 21,100,000Source | 21,848,000Source |
| Operating Lease, ExpenseUSD | — | — | 100,000Source | 200,000Source | 100,000Source | 100,000Source | — | — | 600,000Source | 700,000Source | 800,000Source | 900,000Source |
| Other Operating Income (Expense), NetUSD | — | — | -115,000Source | -394,000Source | 9,000Source | -16,000Source | 10,000Source | 21,000Source | -142,000Source | — | — | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | 464,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 150,000Source | 199,000Source | 149,000Source | 173,000Source | 153,000Source | 177,000Source | 642,000Source | 676,000Source | 636,000Source | 703,000Source |
| Selling and Marketing ExpenseUSD | — | — | 2,087,000Source | 2,864,000Source | 2,207,000Source | 2,910,000Source | 2,177,000Source | 2,814,000Source | 9,924,000Source | 11,655,000Source | 10,233,000Source | 9,125,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Interest and Other Income | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Interest Expense, Debt | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
| Other Expenses | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
Offerings
Registration 333-299123
Underwriters: Lake Street Capital Markets, LLC, Laidlaw & Company Ltd.
Filing attachments
ex107.htm · S-1/A · 2026-10-30
Calculation of Filing Fee Tables S-1 INTERPACE BIOSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 Expected year-over-year growth of approximately 15% to 18% compared with Q3 2025 ───────────────────────────────────────────────────────────────────────────────── Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million PARSIPPANY, NJ, October 14, 2026 (GLOBE NEWSWIRE) - Interp…
Read attachment ↗ex107.htm · S-1/A · 2026-10-01
Calculation of Filing Fee Tables S-1 INTERPACE BIOSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex4-1.htm · S-1/A · 2026-10-01
Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES The following summary describes our common stock and the material provisions of our Amended and Restated Certificate of Incorporation, as amended, our Amended and Restated Bylaws, and the Delaware General Corporation Law (the “DGCL”). Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our certificate of incorporation, bylaws and the …
Read attachment ↗ex107.htm · S-1 · 2026-09-25
Calculation of Filing Fee Tables S-1 INTERPACE BIOSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex107.htm · S-8 · 2026-09-17
Calculation of Filing Fee Tables S-8 INTERPACE BIOSCIENCES, INC. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit …
Read attachment ↗